22 December 2022
SHARE NOW
ATW
Automation & Digitisation
Cell Therapy
Edwin Stone, CEO of Cellular Origins, a TTP Company, describes the importance of a smooth clinical to commercial translation and how implementing innovative tools and technologies can support this.
Edwin discusses the need for robust planning in order to accommodate the changing environment we’re working in, prioritizing collaboration and a commitment to finding technological solutions to ensure success.
Edwin also goes on to share how TTP identify gaps in the market to support the industry, with Cellular Origins tackling the manufacturing bottleneck to bring more therapies to patients.
Don’t miss Cellular Origins at Advanced Therapies Week 2023 – book your tickets today!
This interview has been produced in partnership with Cellular Origins, a TTP Company, ahead of Advanced Therapies Week 2023.
 |
 |
More like this
FDA Investigating ‘Serious Risk’ of Secondary Malignancy Linked to BCMA- or CD19-Directed CAR-T Immunotherapies
FDA investigates T cell malignancy risks in BCMA- and CD19-directed CAR-T therapies.
29 November 2023
Sernova’s Hemophilia A Program Receives Orphan Drug and Rare Pediatric Disease Designations from FDA
Sernova has announced that the FDA has granted both ODD and RPDD for the company’s Hemophilia A program.
28 November 2023
Positive Clinical Results in Myotubular Myopathy Demonstrate Impact on Respiratory and Motor Functions Amidst Severe Challenges
Clinical results of a gene therapy trial conducted by Astellas Gene Therapies, using a drug candidate developed at Généthon were published in The Lancet Neurology.
23 November 2023
Discover more like this
